Michael Hunter

Orca Pharmaceuticals Ltd. operates as a biotechnology company that develops oral drugs for the treatment of chronic inflammatory diseases. It also develops oral drug for the treatment a spectrum of autoimmune diseases that includes psoriasis, ankylosing spondylitis and inflammatory bowel disease. The company was founded by Michael Hunter, Roy Pettipher, Dan Littman, and Jun R. Huh in 2012 and is headquartered in Abingdon, the United Kingdom.

Atopix Therapeutics Ltd. develops medicines to treat atopic dermatitis and severe asthma. The firm also assess the safety and pharmacokinetic profile of its back-up molecule ATX2417 in a phase I study. The company was incorporated on October 10, 2012 and is headquartered in Abingdon, the United Kingdom.

Orca Pharmaceuticals Ltd. operates as a biotechnology company that develops oral drugs for the treatment of chronic inflammatory diseases. It also develops oral drug for the treatment a spectrum of autoimmune diseases that includes psoriasis, ankylosing spondylitis and inflammatory bowel disease. The company was founded by Michael Hunter, Roy Pettipher, Dan Littman, and Jun R. Huh in 2012 and is headquartered in Abingdon, the United Kingdom.

Orca Pharmaceuticals Ltd. operates as a biotechnology company that develops oral drugs for the treatment of chronic inflammatory diseases. It also develops oral drug for the treatment a spectrum of autoimmune diseases that includes psoriasis, ankylosing spondylitis and inflammatory bowel disease. The company was founded by Michael Hunter, Roy Pettipher, Dan Littman, and Jun R. Huh in 2012 and is headquartered in Abingdon, the United Kingdom.

Orca Pharmaceuticals Ltd. operates as a biotechnology company that develops oral drugs for the treatment of chronic inflammatory diseases. It also develops oral drug for the treatment a spectrum of autoimmune diseases that includes psoriasis, ankylosing spondylitis and inflammatory bowel disease. The company was founded by Michael Hunter, Roy Pettipher, Dan Littman, and Jun R. Huh in 2012 and is headquartered in Abingdon, the United Kingdom.

Orca Pharmaceuticals Ltd. operates as a biotechnology company that develops oral drugs for the treatment of chronic inflammatory diseases. It also develops oral drug for the treatment a spectrum of autoimmune diseases that includes psoriasis, ankylosing spondylitis and inflammatory bowel disease. The company was founded by Michael Hunter, Roy Pettipher, Dan Littman, and Jun R. Huh in 2012 and is headquartered in Abingdon, the United Kingdom.